Pulmonary Adenocarcinoma with Enteric Differentiation Presenting with Bronchorrhea

Prakobkit, Ritbune; Auyeung, William Churk-Nam; Xu, Lei; Berry, Gerald J.

doi:10.1016/j.jtho.2017.04.005

Cited by 4 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although PEAC has CT-prone manifestations, the study found no statistically significant difference in metastatic colorectal cancers (MCC) and PEAC (8). Lesions in PEAC always manifested as solid or part-solid nodules or masses (5,8,10,(12)(13)(14)(15)17,19,30,(33)(34)(35), with boundaries clearly, which were similar to typical lung adenocarcinoma (4).…”

Section: Imaging Featuresmentioning

confidence: 94%

“…We organized and analyzed all data in the current literature (Table 1). The results showed that the lesions were more commonly distributed on the right lung tissues, and the ratio of lesions located in the right lung in comparison to the left lung was about 66:49 (1,(8)(9)(10)(11)(12)(13)(15)(16)(17)(19)(20)(21)(22)(23)25,27,30,31,(34)(35)(36) (1,(8)(9)(10)12,13,(15)(16)(17)(18)(19)(20)(21)23,25,27,(30)(31)(32)(33)(34)(35). It was not clearly that the ratio about central lung carcinomas and the peripheral ones.…”

Section: Imaging Featuresmentioning

confidence: 99%

“…Almost 51.2% (22/43) of the patients in these literatures went to the doctor for coughing and 20.9% (9/43) for chest or back pain. The probability of hemoptysis, fever, and cystic mass were relatively lower, at about 16.3% (7/43), 11.6% (5/43), and 11.6% (5/43) respectively (1,6,8,(10)(11)(12)(13)(14)(15)(16)(17)(19)(20)(21). Only a small number of patients from abnormal lesions detected on health examinations, at about 4.7% (2/43).…”

Section: Introductionmentioning

confidence: 98%

“…The following pathologic criterion for PEAC was also set out: if the intestinal differentiation component in lung adenocarcinoma exceeds 50%, the tumor can be classified as PEAC (2). Despite PEAC being subsequently proposed in the 2015 World Health Organization classification, due to the rarity of the disease, systematic guidance or recommendations regarding its diagnosis, treatment, and of respiratory symptoms such as coughing, expectoration, chest pain, dizziness, hemoptysis, fever, bronchitis, and other related discomfort (1,(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21). Almost 51.2% (22/43) of the patients in these literatures went to the doctor for coughing and 20.9% (9/43) for chest or back pain.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Pulmonary enteric adenocarcinoma: a literature review

Li¹,

Cao²

2020

J Thorac Dis

View full text Add to dashboard Cite

prognosis are lacking (3). Therefore, collecting, collating and analyzing data relating to the imaging, laboratory investigation, pathology, immunohistochemistry (IHC), clinical treatment, and prognosis of PEAC, would be of great significance. MethodsWe searched for articles about PEAC from PubMed, CNKI for the words pulmonary, lung, enteric, intestinal, difference and adenocarcinoma. All the date obtained from existing literatures were collated by Microsoft Office application. Clinical pathological featuresClinical characteristics of PEAC were similar to that of typical lung cancer (4). Most patients with PEAC complain

show abstract

Section: Imaging Featuresmentioning

confidence: 94%

Section: Imaging Featuresmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pulmonary enteric adenocarcinoma: a literature review

Li¹,

Cao²

2020

J Thorac Dis

View full text Add to dashboard Cite

show abstract

“…Most studies were single-case reports or small patient series (Refs 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 16, 17, 21, 22, 29, 30, 31, 32, 34, 35, 36, 37, 38, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61) whereas sporadic cases were also described within larger studies on lung cancer, from which it was not always possible to retrieve demographic and clinical information (Refs 62, 63, 64, 65).…”

Section: Analysis Of Literature Datamentioning

confidence: 99%

Pulmonary enteric adenocarcinoma: an overview

Palmirotta

Lovero

D’Oronzo

et al. 2020

Expert Rev. Mol. Med.

View full text Add to dashboard Cite

Most commonly described as sporadic, pulmonary adenocarcinoma with enteric differentiation (PAED) is a rare variant of invasive lung cancer recently established and recognised by the World Health Organization. This tumour is highly heterogeneous and shares several morphological features with pulmonary and colorectal adenocarcinomas. Our objective is to summarise current research on PAED, focusing on its immunohistochemical and molecular features as potential tools for differential diagnosis from colorectal cancer, as well as prognosis definition and therapeutic choice. PAED exhibits an ‘entero-like’ pathological morphology in more than half cases, expressing at least one of the typical immunohistochemical markers of enteric differentiation, namely CDX2, CK20 or MUC2. For this reason, this malignancy appears often indistinguishable from a colorectal cancer metastasis, making the differential diagnosis laborious. Although standard diagnostic criteria have not been established yet, in the past few years, a number of approaches have been addressed, aimed at defining specific immunohistochemical and molecular signatures. Based on previously published literature, we have collected and analysed molecular and immunohistochemical data on this rare neoplasm, and have described the state of the art on diagnostic criteria as well as major clinical and therapeutic implications. The analysis of data from 295 patients from 58 published articles allowed us to identify the most represented immunohistochemical and molecular markers, as well as major differences between Asian PAEDs and those diagnosed in European/North American countries. The innovative molecular approaches, exploring driver mutations or new gene alterations, could help to identify rare prognostic factors and guide future tailored therapeutic approaches to this rare neoplasm.

show abstract